Investor FAQs

Show All
What does MaxCyte do?

At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. 

Where is Maxcyte headquartered?

MaxCyte is headquartered in Rockville, Maryland, USA. 9713 Key West Avenue, Suite 400 Rockville, MD 20850, United States. 

On what stock exchange are MaxCyte shares traded and what is the ticker?

MaxCyte is listed on the NASDAQ stock exchange under the ticker symbol “MXCT”.

When did MaxCyte go public, and what was the offering price?

MaxCyte’s initial public offering was on July 29, 2021 at a price of $13 per share.

What is MaxCyte’s fiscal year end?

MaxCyte’s fiscal year ends on December 31.

Does MaxCyte offer a direct stock purchase plan?

MaxCyte does not currently offer a direct stock purchase plan.

Where can I find MaxCyte’s SEC filings? Where can I download and view quarterly and annual reports?

Quarterly and annual reports, as well as other SEC filings, can be accessed here on our Investor Relations website or directly from the SEC at www.sec.gov.

Who are the company’s independent registered public accountants?

MaxCyte’s independent registered public accounting firm is CohnReznick LLP.

Who is the company’s transfer agent?

Our transfer agent is Computershare Trust Company, N.A. They can be reached at:

 

Website: www.computershare.com/us

Email: Use the contact form at www.computershare.com/us/contact

Telephone: 1‑800‑736‑3001 (U.S. & Canada) or 1‑781‑575‑3100 (International)

 

Regular Mail

Computershare

P.O. Box 43078

Providence, RI 02940‑3078

 

Overnight Mail

Computershare

150 Royall Street, Suite 101

Canton, MA 02021

 

Registered stockholders should contact Computershare in the event of a name change, address update, or if their certificate has been lost or stolen.

If a registered stockholder does not receive notification of the availability of our proxy statement and annual report prior to the Annual Meeting, Computershare is the appropriate contact.

 

Who are the members of MaxCyte’s Board of Directors?

You can view our Board of Directors by visiting the Board of Directors section of our website here.

Who are the members of MaxCyte’s management team?

You can view our management team by visiting the Management Team section of our website here. 

Where can I get the latest corporate news releases and financial reports?

Our latest press releases can be found here, and financial reports can be found here.

How can I get on your Investor Relations email list?

You can join our Investor Relations email list here.

How do I contact Investor Relations with a question or request?

For investor inquiries, please contact IR@maxcyte.com. You may also submit questions via the “Contact IR” page here.